JP2020073564A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020073564A5 JP2020073564A5 JP2020001832A JP2020001832A JP2020073564A5 JP 2020073564 A5 JP2020073564 A5 JP 2020073564A5 JP 2020001832 A JP2020001832 A JP 2020001832A JP 2020001832 A JP2020001832 A JP 2020001832A JP 2020073564 A5 JP2020073564 A5 JP 2020073564A5
- Authority
- JP
- Japan
- Prior art keywords
- indirubin
- composition
- average particle
- particle size
- effective average
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical compound N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 claims 46
- 239000000203 mixture Substances 0.000 claims 25
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 claims 23
- CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 claims 23
- 239000002245 particle Substances 0.000 claims 18
- 239000003381 stabilizer Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 4
- 150000003868 ammonium compounds Chemical class 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 108010039918 Polylysine Proteins 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960001305 cysteine hydrochloride Drugs 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001804 emulsifying effect Effects 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- -1 fatty acid ester Chemical class 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000008297 liquid dosage form Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000003801 milling Methods 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000656 polylysine Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims 1
- 238000001238 wet grinding Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021118361A JP2021181447A (ja) | 2012-06-21 | 2021-07-19 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
| JP2023021518A JP2023062070A (ja) | 2012-06-21 | 2023-02-15 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662469P | 2012-06-21 | 2012-06-21 | |
| US61/662,469 | 2012-06-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018144837A Division JP2018199685A (ja) | 2012-06-21 | 2018-08-01 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021118361A Division JP2021181447A (ja) | 2012-06-21 | 2021-07-19 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020073564A JP2020073564A (ja) | 2020-05-14 |
| JP2020073564A5 true JP2020073564A5 (https=) | 2020-06-25 |
Family
ID=49769412
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015518599A Active JP6382187B2 (ja) | 2012-06-21 | 2013-06-21 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
| JP2018144837A Pending JP2018199685A (ja) | 2012-06-21 | 2018-08-01 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
| JP2020001832A Pending JP2020073564A (ja) | 2012-06-21 | 2020-01-09 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
| JP2021118361A Pending JP2021181447A (ja) | 2012-06-21 | 2021-07-19 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
| JP2023021518A Pending JP2023062070A (ja) | 2012-06-21 | 2023-02-15 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015518599A Active JP6382187B2 (ja) | 2012-06-21 | 2013-06-21 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
| JP2018144837A Pending JP2018199685A (ja) | 2012-06-21 | 2018-08-01 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021118361A Pending JP2021181447A (ja) | 2012-06-21 | 2021-07-19 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
| JP2023021518A Pending JP2023062070A (ja) | 2012-06-21 | 2023-02-15 | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10039829B2 (https=) |
| EP (2) | EP3597178A1 (https=) |
| JP (5) | JP6382187B2 (https=) |
| CN (2) | CN110123763A (https=) |
| CA (1) | CA2914782C (https=) |
| WO (1) | WO2013192493A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110123763A (zh) * | 2012-06-21 | 2019-08-16 | 法斯瑞斯公司 | 靛玉红的奈米粒子、其衍生物以及制造和使用所述奈米粒子的方法 |
| WO2015095659A2 (en) * | 2013-12-20 | 2015-06-25 | Phosphorex, Inc. | Indirubin solid dispersion composition |
| RU2630561C2 (ru) * | 2015-10-20 | 2017-09-11 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России | Способ получения водно-солевых дисперсий фуллерена |
| JP2020515598A (ja) * | 2017-03-29 | 2020-05-28 | フォスフォレックス，インコーポレーテッド | インジルビン及びその誘導体を含有する新規の医薬製剤並びにその製造方法及び使用方法 |
| RU2721318C1 (ru) * | 2019-02-28 | 2020-05-18 | Автономная некоммерческая образовательная организация высшего образования "Сколковский институт науки и технологий" | Способ получения золей и суспензий |
| US20200345645A1 (en) * | 2019-05-03 | 2020-11-05 | Azora Therapeutics, Inc. | Compositions comprising indigo and/or an indigo derivative and methods of use thereof |
| CN114668744A (zh) * | 2022-03-23 | 2022-06-28 | 成都大学 | 一种靛玉红固体脂质纳米粒及其制备方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4929242A (en) * | 1986-11-26 | 1990-05-29 | Baxter International Inc. | Solution and method for maintaining patency of a catheter |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| TW384224B (en) * | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
| US7998507B2 (en) * | 2000-09-21 | 2011-08-16 | Elan Pharma International Ltd. | Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors |
| DE10129028A1 (de) * | 2001-06-11 | 2003-01-02 | Schering Ag | Lösliche Cdk-inhibitorische Indirubinderivate |
| US20050154046A1 (en) | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| CA2469649C (en) * | 2001-12-13 | 2011-05-03 | Natrogen Therapeutics, Inc. | Derivatives of isoindigo, indigo and indirubin and use in treating cancer |
| EP1490030B2 (en) * | 2002-03-20 | 2010-07-14 | Elan Pharma International Limited | Nanoparticulate compositions of angiogenesis inhibitors |
| US20080220074A1 (en) * | 2002-10-04 | 2008-09-11 | Elan Corporation Plc | Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same |
| JP2006520392A (ja) * | 2003-03-13 | 2006-09-07 | コントロールド・ケミカルズ・インコーポレーテッド | 薬物の乱用可能性を低下させ且つ作用持続時間を延長する化合物および方法 |
| CN1615852A (zh) * | 2003-11-10 | 2005-05-18 | 许军 | 靛玉红口服滴丸及制备工艺 |
| KR100588803B1 (ko) * | 2004-01-27 | 2006-06-12 | 학교법인조선대학교 | 암세포주에 항암활성을 지닌 인디루빈 유도체 |
| UA89513C2 (uk) | 2004-12-03 | 2010-02-10 | Элан Фарма Интернешнл Лтд. | Стабільна композиція з наночастинок ралоксифену гідрохлориду |
| CA2590675A1 (en) * | 2004-12-15 | 2006-06-22 | Elan Pharma International Ltd. | Nanoparticulate tacrolimus formulations |
| WO2006069098A1 (en) * | 2004-12-22 | 2006-06-29 | Elan Pharma International Ltd. | Nanoparticulate bicalutamide formulations |
| KR20070118224A (ko) * | 2005-01-06 | 2007-12-14 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 칸데사르탄 제제 |
| MX2007010394A (es) * | 2005-02-24 | 2008-02-19 | Elan Pharma Int Ltd | Formulaciones nanoparticuladas de docetaxel y analogos del mismo. |
| US20060204588A1 (en) * | 2005-03-10 | 2006-09-14 | Elan Pharma International Limited | Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof |
| CN101198316A (zh) * | 2005-03-17 | 2008-06-11 | 伊兰制药国际有限公司 | 纳米微粒双膦酸盐组合物 |
| WO2006102494A2 (en) * | 2005-03-23 | 2006-09-28 | Elan Pharma International Limited | Nanoparticulate corticosteroid and antihistamine formulations |
| EP1871345B1 (en) * | 2005-04-12 | 2012-08-01 | Elan Pharma International Limited | Nanoparticulate erlotinib formulations |
| US7825087B2 (en) * | 2005-04-12 | 2010-11-02 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising cyclosporine |
| JP2008545752A (ja) * | 2005-06-02 | 2008-12-18 | テルシカ インコーポレーティッド | 成長障害を処置するための方法 |
| CN101023944A (zh) * | 2006-02-23 | 2007-08-29 | 黎明涛 | 靛玉红衍生物在制备治疗神经退行性变疾病药物中的应用 |
| CN101074229B (zh) * | 2007-06-08 | 2010-09-01 | 无锡杰西医药科技有限公司 | 7-氮杂靛玉红和7-氮杂异靛蓝衍生物制备及其药学用途 |
| EP2057982A1 (en) | 2007-11-09 | 2009-05-13 | Archimedes Development Limited | Intranasal compositions |
| US20090274621A1 (en) * | 2008-03-21 | 2009-11-05 | Adlyfe, Inc | Use of pyrene to carry non-peptide agents across the blood brain barrier |
| PT2113253E (pt) | 2008-04-30 | 2010-06-15 | Immatics Biotechnologies Gmbh | Formulações novas de peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla) para vacinas |
| CN101362066B (zh) * | 2008-09-27 | 2010-12-22 | 同济大学 | 脂质体包埋量子点的二氧化硅微球的制备方法及其产品 |
| CN101775082B (zh) * | 2010-02-09 | 2012-06-27 | 中国药科大学 | 基于两性离子的电荷反转型壳聚糖衍生物及其在药剂中的应用 |
| CN102018736B (zh) * | 2010-11-19 | 2012-03-28 | 成都中医药大学 | 一种青黛饮片及其制备方法 |
| CN102228433B (zh) * | 2011-06-29 | 2012-11-28 | 上海中医药大学 | 过饱和自微乳制剂及其制备方法和应用 |
| CN110123763A (zh) * | 2012-06-21 | 2019-08-16 | 法斯瑞斯公司 | 靛玉红的奈米粒子、其衍生物以及制造和使用所述奈米粒子的方法 |
-
2013
- 2013-06-21 CN CN201910470369.1A patent/CN110123763A/zh active Pending
- 2013-06-21 JP JP2015518599A patent/JP6382187B2/ja active Active
- 2013-06-21 CN CN201380043697.4A patent/CN104602675B/zh active Active
- 2013-06-21 WO PCT/US2013/046981 patent/WO2013192493A1/en not_active Ceased
- 2013-06-21 EP EP19180122.4A patent/EP3597178A1/en not_active Withdrawn
- 2013-06-21 CA CA2914782A patent/CA2914782C/en active Active
- 2013-06-21 EP EP13806153.6A patent/EP2863897B1/en active Active
-
2014
- 2014-12-17 US US14/573,212 patent/US10039829B2/en active Active
-
2018
- 2018-07-20 US US16/040,640 patent/US10675350B2/en active Active
- 2018-08-01 JP JP2018144837A patent/JP2018199685A/ja active Pending
-
2020
- 2020-01-09 JP JP2020001832A patent/JP2020073564A/ja active Pending
-
2021
- 2021-07-19 JP JP2021118361A patent/JP2021181447A/ja active Pending
- 2021-09-09 US US17/470,163 patent/US20220168423A1/en not_active Abandoned
-
2023
- 2023-02-15 JP JP2023021518A patent/JP2023062070A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020073564A5 (https=) | ||
| Jacob et al. | Emerging role of nanosuspensions in drug delivery systems | |
| JP4623966B2 (ja) | 表面安定剤としてチロキサポールを含有する、濾過滅菌したブデソニドおよびベクロメタゾンのナノ粒子製剤 | |
| EP3513809B1 (en) | Medicinal composition comprising tivozanib | |
| EP3741747B1 (en) | Method for preventing and/or treating anxiety | |
| JP2010111685A (ja) | 表面安定剤として共重合体を含むナノ粒子組成物 | |
| Suresh et al. | Nanocarriers for ocular delivery for possible benefits in the treatment of anterior uveitis: focus on current paradigms and future directions | |
| ES2884849T3 (es) | Composiciones de profármaco de aripiprazol | |
| WO2020034989A1 (zh) | 一种可注射的药物组合物及其制备方法 | |
| Shi et al. | Biodegradable nanoparticle flocculates for dry powder aerosol formulation | |
| US10251866B2 (en) | Pharmaceutical nanosuspension | |
| Liu | Nanocrystal formulation for poorly soluble drugs | |
| Garg et al. | Current nanotechnological approaches for an effective delivery of bioactive drug molecules to overcome drug resistance tuberculosis | |
| JP2015520241A5 (https=) | ||
| JP2017527600A5 (https=) | ||
| JP2012505236A (ja) | コルチコステロイド組成物およびそれの治療方法 | |
| Ortiz et al. | Intranasal administration of budesonide-loaded nanocapsule microagglomerates as an innovative strategy for asthma treatment | |
| JP5037939B2 (ja) | マイクロエマルジョンおよび気道疾患を防ぐためのその使用 | |
| ES2893973T3 (es) | Composiciones de múltiples profármacos de aripiprazol | |
| JPH1192368A (ja) | ベンゾピラン誘導体を主成分とする水性液剤 | |
| JP2019533008A5 (https=) | ||
| JP2019531344A5 (https=) | ||
| ES2721270T5 (es) | Composiciones de profármaco de aripiprazol | |
| US10201552B2 (en) | Method of increasing the bioavailability of an HIV drug | |
| CN102573815B (zh) | Hiv感染的治疗和预防 |